Q2 2026 saw strong operational execution, with Adjusted EBITDA up 13.9% and EPS up 42.6% year-over-year, despite lower net sales due to a divestiture. Raised full-year guidance reflects robust first-half results, improved margins, and disciplined capital allocation.Original document: Ingevity Corpo…
Q2 2026 saw strong operational execution, with Adjusted EBITDA up 13.9% and EPS up 42.6% year-over-year, despite lower net sales due to a divestiture. Raised full-year guidance reflects robust first-half results, improved margins, and disciplined capital allocation.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.